Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 1, 2026, 5:36 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 253 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: PPI Clear all
Completed Phase 4 Interventional Results available

The CALIBER Study Randomized Controlled Trial of LINX Versus Double-Dose Proton Pump Inhibitor Therapy for Reflux Disease

NCT02505945
View directory record Official record
Conditions
GERD Gastroesophageal Reflux Disease
Interventions
Omeprazole, LINX Reflux Management System
Drug · Device
Lead sponsor
Torax Medical Incorporated
Industry
Eligibility
21 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
21
States / cities
Mobile, Alabama • Heber Springs, Arkansas • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2019 · Synced Sep 1, 2026, 5:36 PM EDT
Completed Not applicable Interventional Results available

Randomized EsophyX Versus Sham / Placebo Controlled TIF Trial: The RESPECT Study

NCT01136980
View directory record Official record
Conditions
Gastroesophageal Reflux Disease, Hiatal Hernia
Interventions
TIF Transoral Fundoplication, Sham placebo procedure
Device · Other
Lead sponsor
EndoGastric Solutions
Industry
Eligibility
18 Years to 80 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
9
States / cities
Los Angeles, California • Englewood, Colorado • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2021 · Synced Sep 1, 2026, 5:36 PM EDT
Not listed Phase 1 Interventional

The Safety and Tolerability of Secretrol in Patients With Barrett's Esophagus

NCT01905202
View directory record Official record
Conditions
Barrett's Esophagus
Interventions
Secretrol
Drug
Lead sponsor
Effexus Pharmaceutical
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 3, 2014 · Synced Sep 1, 2026, 5:36 PM EDT
Completed Not applicable Interventional

Transoral Incisionless Fundoplication (TIF) Registry Study for Treatment of Gastroesophageal Reflux Disease (GERD)

NCT01118585
View directory record Official record
Conditions
Gastroesophageal Reflux Disease, Hiatal Hernia
Interventions
TIF Procedure
Procedure
Lead sponsor
EndoGastric Solutions
Industry
Eligibility
18 Years to 75 Years
Enrollment
278 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
14
States / cities
Safford, Arizona • Tempe, Arizona • Englewood, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2019 · Synced Sep 1, 2026, 5:36 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Effect of Increased Gastric pH on the Oral Bioavailability of the Orexin-2 Receptor Antagonist JNJ-42847922 in Healthy Participants

NCT02475161
View directory record Official record
Conditions
Healthy
Interventions
JNJ-42847922, Rabeprazole
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 2, 2025 · Synced Sep 1, 2026, 5:36 PM EDT
Completed Not applicable Interventional Results available

Ablation of Intestinal Metaplasia Containing Dysplasia

NCT00282672
View directory record Official record
Conditions
Barrett Esophagus
Interventions
Ablation System plus anti-secretory medication, Sham procedure plus anti-secretory medication
Device
Lead sponsor
Medtronic - MITG
Industry
Eligibility
18 Years to 80 Years
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
19
States / cities
Scottsdale, Arizona • Tucson, Arizona • Orange, California + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2017 · Synced Sep 1, 2026, 5:36 PM EDT
Completed Not applicable Interventional Results available

A Clinical Trial of Proton Pump Inhibitors to Treat Children With Chronic Otitis Media With Effusion

NCT00546117
View directory record Official record
Conditions
Otitis Media With Effusion
Interventions
lansoprazole, placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
2 Years to 12 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 31, 2018 · Synced Sep 1, 2026, 5:36 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Pharmacokinetic Drug-Drug Interactions of Lemborexant When Coadministered With an Oral Contraceptive, Famotidine, or Fluconazole in Healthy Subjects

NCT03451110
View directory record Official record
Conditions
Healthy Subjects
Interventions
lemborexant, Loestrin, famotidine, fluconazole
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 5, 2018 · Synced Sep 1, 2026, 5:36 PM EDT
Completed Phase 4 Interventional Results available

Ketamine Infusion Therapy for the Management of Acute Pain in Adult Rib Fracture Patients

NCT02432456
View directory record Official record
Conditions
Wounds and Injuries, Rib Fractures
Interventions
Ketamine, Placebo, Intercostal Nerve Block, Acetaminophen, Ibuprofen, Pantoprazole, Methocarbamol, Opioid
Drug · Procedure
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 4, 2020 · Synced Sep 1, 2026, 5:36 PM EDT
Withdrawn Phase 2 Interventional

A Phase II Trial of Proton Pump Inhibitors With Chemotherapy in Patients With Metastatic Head and Neck Cancer

NCT02013453
View directory record Official record
Conditions
Cancer of Head and Neck
Interventions
Omeprazole, Carboplatin, 5FU, Paclitaxel, Pemetrexed
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 1, 2014 · Synced Sep 1, 2026, 5:36 PM EDT
Completed Phase 2 Interventional Results available

A Study to Estimate Effect of 4 Different Doses of AZD3355 on Reflux Episodes, Which Patients With Gastroesophageal Reflux Disease (GERD) May Experience

NCT01043185
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
AZD3355, placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jun 13, 2011 · Synced Sep 1, 2026, 5:36 PM EDT
Completed No phase listed Observational

Proton Pump Inhibitor (PPI) Responsive Eosinophilic Esophagitis EoE: Gastroesophageal Reflux Disease (GERD) or Eosinophilic Esophagitis (EoE)?

NCT01865825
View directory record Official record
Conditions
Erosive Esophagitis
Interventions
Esophageal Barium Xray
Radiation
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 21, 2017 · Synced Sep 1, 2026, 5:36 PM EDT
Completed Early Phase 1 Interventional

Neurobiology of Functional Movement Disorder and Non-Epileptic Seizures

NCT00500994
View directory record Official record
Conditions
Movement Disorders
Interventions
MRI
Device
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 99 Years
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2022
U.S. locations
2
States / cities
Bethesda, Maryland • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced Sep 1, 2026, 5:36 PM EDT
Completed Phase 1Phase 2 Interventional

Deprescribing Proton Pump Inhibitors to Reduce Post-TIPS Hepatic Encephalopathy

NCT05070351
View directory record Official record
Conditions
Hepatic Encephalopathy
Interventions
PPI deprescribing
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 22, 2025 · Synced Sep 1, 2026, 5:36 PM EDT
Completed Phase 4 Interventional Results available

Impact of Timing on the Efficacy of Zegerid 40 mg in Healing Reflux Esophagitis: A Pilot Study

NCT00693225
View directory record Official record
Conditions
Erosive Esophagitis
Interventions
Omeprazole/sodium bicarbonate
Drug
Lead sponsor
Yvonne Romero
Other
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 19, 2012 · Synced Sep 1, 2026, 5:36 PM EDT
Completed Phase 2 Interventional Results available

Selective 5-HT4 Receptor Agonist and Proton Pump Inhibitor (PPI) in Subjects With Gastroesophageal Reflux Disease (GERD)

NCT01472939
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
SSP-002358 (0.1 mg) + PPI, SSP-002358 (0.5 mg) + PPI, SSP-002358 (2.0 mg) + PPI, Placebo + PPI
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 70 Years
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
62
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 58 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Sep 1, 2026, 5:36 PM EDT
Recruiting Not applicable Interventional

Optimizing Proton Pump Inhibitors (PPI) Prescribing With EHR-Based Decision Support

NCT06998966
View directory record Official record
Conditions
Prescribing Patterns, Physician, Physician's Practice Patterns, Drug Utilization Review
Interventions
Algorithmic Defaulting (Indication-Based Default), Active Physician Choice
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
50 Years and older
Enrollment
372 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Sep 1, 2026, 5:36 PM EDT
Recruiting Not applicable Interventional

A Study of Breath Testing for Small Intestinal Bacterial Overgrowth

NCT05976165
View directory record Official record
Conditions
Gastroesophageal Reflux, Regurgitation, Heartburn
Interventions
Breath Testing
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Sep 1, 2026, 5:36 PM EDT
Completed Phase 3 Interventional

Assessment of the Role of Tegaserod Therapy in the Management of Gastroesophageal Reflux Disease (GERD) Symptoms in Patients With Incomplete Response to Proton Pump Inhibitors (PPIs).

NCT00171483
View directory record Official record
Conditions
Gastroesophageal Reflux Disease (GERD)
Interventions
Tegaserod
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Timeline
2004 – 2005
U.S. locations
7
States / cities
Boynton Beach, Florida • Miami, Florida • Pembroke Pines, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2008 · Synced Sep 1, 2026, 5:36 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Esomeprazole on the Pharmacokinetics of Oral Treprostinil

NCT00963027
View directory record Official record
Conditions
Hypertension, Pulmonary, Pulmonary Arterial Hypertension
Interventions
Treprostinil diethanolamine, Esomeprazole
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 7, 2010 · Synced Sep 1, 2026, 5:36 PM EDT
Completed Phase 3 Interventional

Efficacy/Safety of Lansoprazole in Patients With Frequent Heartburn

NCT00389948
View directory record Official record
Conditions
Heartburn
Interventions
Lanzoprazole
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
576 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
28
States / cities
Hoover, Alabama • Huntsville, Alabama • Sierra Vista, Arizona + 23 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2007 · Synced Sep 1, 2026, 5:36 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacodynamic and Pharmacokinetic Study of E3710 Following Oral Administration to Healthy, Male, Japanese Subjects

NCT01390714
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
E3710
Drug
Lead sponsor
Eisai Co., Ltd.
Industry
Eligibility
20 Years to 40 Years · Male only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Mar 13, 2012 · Synced Sep 1, 2026, 5:36 PM EDT
Completed No phase listed Observational

Positive Predictive Value of the Dx-pH Probe for Predicting PPI Response in LPR

NCT01755221
View directory record Official record
Conditions
Laryngopharyngeal Reflux (LPR), Extraesophageal Reflux, Reflux Laryngitis, Posterior Laryngitis
Interventions
Not listed
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 89 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Sep 1, 2026, 5:36 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Precision Approach to PPI Therapy in Gastroesophageal Reflux Disease

NCT03619811
View directory record Official record
Conditions
Gastroesophageal Reflux, Laryngopharyngeal Reflux
Interventions
Reflux Band® Upper Esophageal Sphincter (UES) Assist Device
Diagnostic Test
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 89 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Sep 19, 2021 · Synced Sep 1, 2026, 5:36 PM EDT